Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

Recombinant Human KIR3DS1/CD158e2 Fc Chimera (Catalog # 4136-KR)binds toMDA-MB-231 human breast cancer cells. The ED50 for this effect is0.03-0.18 μg/mL.

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind HLA on MDA‑MB‑231 human breast cancer cells. The ED₅₀ for this effect is 0.03-0.18 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human KIR3DS1/CD158e2 protein
  

  Human KIR3DS1 (His22-His340) Accession #Q14943	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q14943
• N-terminal Sequence: His22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: KIR3DS1
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 61.9 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 75-90 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

• CD158e2
• KIR3DS1
• KIR-G1
• nkat10

Background

KIR3DS1 (3DS1, CD158e2) is a type I transmembrane protein that belongs to the killer cell Ig-like receptor (KIR) family. KIRs are expressed on CD56^dim NK cells and T cell subsets where they differentiate normal from abnormal cells, and regulate effector functions in the innate immune system (1 - 3). KIRs are named for the number of Ig-like domains (2D or 3D) in the extracellular domain (ECD), and whether they have long or short (L, S) cytoplasmic tails. Like other activating KIRs, KIR3DS1 has a short cytoplasmic tail and a positively charged amino acid (aa) within the transmembrane domain that interacts with the ITAM-bearing signaling adaptor, DAP12 (2, 4). Crosslinking of KIR3DS1 activates cytolysis and induces IFN-gamma production, confirming it to be an activating receptor (4). Approximately 38% of the population expresses KIR3DS1 on the surface of NK cells (1, 4, 5). Variants lacking the N-terminal Ig-like domain and/or with substitutions in the cytoplasmic tail have been described (1, 6). The 50 kDa, 387 aa KIR3DS1 shows 97% aa identity with KIR3DL1 within the ECD, and the two segregate as alleles (3, 7). Some activating KIRs bind weakly to the ligands recognized by their corresponding inhibitory KIR. KIR3DS1 does not bind appreciably to cells transfected with ligands for HLA-Bw4 KIR3DL1 (4, 5). However, HIV-infected people who express the combined phenotype of KIR3DS1 with Bw4 alleles that contain an isoleucine at aa 80, show delayed progression to AIDS and fewer AIDS-related opportunistic infections (7, 8). KIR receptors have no structural orthologs in nonprimates, although mouse Ly-49 proteins perform similar functions (2).

1. Dohring, C. et al. (1996) Immunogenetics 44:227.
2. Lanier, L. L. (2005) Annu. Rev. Immunol. 23:225.
3. Uhrberg, M. et al. (1997) Immunity 7:753.
4. Carr, W. H. et al. (2007) J. Immunol. 178:647.
5. O’Connor, G. M. et al. (2007) J. Immunol. 178:235.
6. Valiante, N. M. et al. (1997) Immunity 7:739.
7. Martin, M. P. et al. (2002) Nat. Genet. 31:429.
8. Qi, Y. et al. (2006) PloS Pathog. 2:e79.

Publications for KIR3DS1/CD158e2 (4136-KR)(4)

Publications using 4136-KR

• A Tremblay-M, S Coenraads, Z Kiani, FP Dupuy, NF Bernard Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function BMC Immunol., 2019;20(1):8. 2019 [PMID: 30696399] (Flow Cytometry, Human)
• Z Kiani, FP Dupuy, J Bruneau, B Lebouché, CX Zhang, E Jackson, I Lisovsky, S da Fonseca, DE Geraghty, NF Bernard HLA-F on HLA-Null 721.221 Cells Activates Primary NK Cells Expressing the Activating Killer Ig-like Receptor KIR3DS1 J. Immunol., 2018;0(0):. 2018 [PMID: 29743316] (Bioassay, Human)
• S Ryser, A Estellés, E Tenorio, LM Kauvar, ML Gishizky High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals PLoS ONE, 2017;12(7):e0181464. 2017 [PMID: 28723950] (Bioassay, Human)
• Fadda L, Korner C, Kumar S, van Teijlingen NH, Piechocka-Trocha A, Carrington M, Altfeld M HLA-Cw*0102-Restricted HIV-1 p24 Epitope Variants Can Modulate the Binding of the Inhibitory KIR2DL2 Receptor and Primary NK Cell Function. PLoS Pathog., 2012;8(7):e1002805. 2012 [PMID: 22807681] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: KIR3DS1
• Uniprot:
  • Q14943()